OncoSec Medical Incorporated (ONCS) Financial Analysis & Valuation | Quarter Chart
OncoSec Medical Incorporated (ONCS)
ONCSPrice: $0.28
Fair Value: 🔒
🔒score
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 ... more
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing... more
Description
Shares
| Market Cap | $1.65M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert H. Arch |
| IPO Date | 2010-04-07 | CAGR | — |
| Employees | 40 | Website | oncosec.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ONCS chart loading...
Fundamentals
Technicals
| Enterprise Value | $-162,196 | P/E Ratio | -0.01 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-20.31 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.55% | ROA | -1.56% |
| ROCE | -2.43% | Current Ratio | 2.3 |
| Quick Ratio | 2.3 | Cash Ratio | 1.85 |
| Debt/Equity | 1.01 | Interest Coverage | -1768.8 |
| Altman Z Score | -59.8 | Piotroski Score | 3 |